Aims: The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS). Methods and results: Patients from the International Takotsubo (InterTAK) Registry were categorized into two groups based on aspirin prescription at discharge. A comparison of clinical outcomes between groups was performed using an adjusted analysis with propensity score (PS) stratification; results from the unadjusted analysis were also reported to note the effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a composite of death, myocardial infarction, TTS recurrence, stroke or transient ischaemic attack) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known status regarding aspirin prescription at discharge were included. According to the adjusted analysis based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.50–3.04, P = 0.64] or 5-year follow-up (HR 1.11, 95% CI 0.78–1.58, P = 0.58). These results were confirmed by sensitivity analyses performed with alternative PS-based methods, i.e. covariate adjustment and inverse probability of treatment weighting. Conclusion: In the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed in adequately powered randomized controlled trials. ClinicalTrials.gov Identifier: NCT01947621.
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry / D'Ascenzo, F.; Gili, S.; Bertaina, M.; Iannaccone, M.; Cammann, V. L.; Di Vece, D.; Kato, K.; Saglietto, A.; Szawan, K. A.; Frangieh, A. H.; Boffini, B.; Annaratone, M.; Sarcon, A.; Levinson, R. A.; Franke, J.; Napp, L. C.; Jaguszewski, M.; Noutsias, M.; Munzel, T.; Knorr, M.; Heiner, S.; Katus, H. A.; Burgdorf, C.; Schunkert, H.; Thiele, H.; Bauersachs, J.; Tschope, C.; Pieske, B. M.; Rajan, L.; Michels, G.; Pfister, R.; Cuneo, A.; Jacobshagen, C.; Hasenfuss, G.; Karakas, M.; Koenig, W.; Rottbauer, W.; Said, S. M.; Braun-Dullaeus, R. C.; Banning, A.; Cuculi, F.; Kobza, R.; Fischer, T. A.; Vasankari, T.; Airaksinen, K. E. J.; Opolski, G.; Dworakowski, R.; Maccarthy, P.; Kaiser, C.; Osswald, S.; Galiuto, L.; Crea, F.; Dichtl, W.; Franz, W. M.; Empen, K.; Felix, S. B.; Delmas, C.; Lairez, O.; El-Battrawy, I.; Akin, I.; Borggrefe, M.; Horowitz, J. D.; Kozel, M.; Tousek, P.; Widimsky, P.; Gilyarova, E.; Shilova, A.; Gilyarov, M.; Biondi-Zoccai, G.; Winchester, D. E.; Ukena, C.; Neuhaus, M.; Bax, J. J.; Prasad, A.; Di Mario, C.; Bohm, M.; Gasparini, M.; Ruschitzka, F.; Bossone, E.; Citro, R.; Rinaldi, M.; De Ferrari, G. M.; Luscher, T.; Ghadri, J. R.; Templin, C.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 22:2(2020), pp. 330-337. [10.1002/ejhf.1698]
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry
D'Ascenzo F.;Bossone E.;Citro R.;
2020
Abstract
Aims: The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS). Methods and results: Patients from the International Takotsubo (InterTAK) Registry were categorized into two groups based on aspirin prescription at discharge. A comparison of clinical outcomes between groups was performed using an adjusted analysis with propensity score (PS) stratification; results from the unadjusted analysis were also reported to note the effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a composite of death, myocardial infarction, TTS recurrence, stroke or transient ischaemic attack) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known status regarding aspirin prescription at discharge were included. According to the adjusted analysis based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.50–3.04, P = 0.64] or 5-year follow-up (HR 1.11, 95% CI 0.78–1.58, P = 0.58). These results were confirmed by sensitivity analyses performed with alternative PS-based methods, i.e. covariate adjustment and inverse probability of treatment weighting. Conclusion: In the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed in adequately powered randomized controlled trials. ClinicalTrials.gov Identifier: NCT01947621.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
